TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05899972

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo technique
Description: With the volunteer in a supine position, the researcher placed the palms of their hands on the patient's shoulders. The contact is made with the hands on the shoulder blades of the volunteer for 6 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suboccipital inhibition technique
Description: With the volunteer in a supine position, the investigator is sitting position at the patient's bedside. The investigator starts by placing both hands under the patient's head in the occipital region. After palpating the suboccipital muscles, the investigator uses the second, third and fourth fingers of both hands flexed against the muscle belly and remains in this position.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frontal lift technique
Description: With the volunteer in a supine position, the investigator is sitting position at the patient's bedside. The investigator positions the tips of both index fingers on either side of the metopic suture while the third finger remains resting on the frontal bone so that the tips of the fourth fingers contact the zygomatic processes bilaterally. A slight pressure is applied with the index fingers and an anterior pressure is performed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parietal lift technique
Description: With the volunteer in a supine position, the investigator is sitting position at the patient's bedside. The investigator places the palms on the lateral edges of the parietal bones and the thumbs crossed at the sagittal suture. First, a medial pressure is administered with the second, third and fourth fingers and then a cephalic traction is performed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IV ventricle technique
Description: With the volunteer in a supine position, the investigator is sitting position at the patient's bedside. The investigator positions his hands in a shell and thumbs together at the level of the spinous apophyses of the patient's second or third cervical vertebra.
Study: NCT06507800

Intervention type: OTHER
Intervention: Observational cohort
Description: Cancer incidence after AHSCT for an autoimmune indication.

Intervention type: OTHER
Intervention: Observational cohort
Description: Cancer incidence after AHSCT for an autoimmune indication.

Intervention type: OTHER
Intervention: Observational cohort
Description: Cancer incidence after AHSCT for an autoimmune indication.
Study: NCT06256419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonist
Description: Eligible patients with T2DM were required to have received GLP-1RA as monotherapy or in combination with other antidiabetic agents. GLP-1 RA was injected subcutaneously at standard dose and frequency for consecutive 6 months in patients with T2DM.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: responders group and nonresponders group
Description: For all the patients with type 2 diabetes who were initially enrolled in the study, blood samples were obtained for genotyping before the administration of GLP-1 receptor agonists. Patients were re-screened according to whether they had used GLP-1 RA continuously for more than 6 months and had completed the specified follow-up tasks.~Patients were divided according to the type of T2DM susceptibility genes. Or all were divided into responses group and nonresponses group according to whether they had glycemic response (△HbA1c↓ ≥1.0%) and weight response (△weight↓ ≥3.0%) after taking GLP-1 receptor agonist for 6 months.~According to the above grouping, the variables that can predict the efficacy of the drug were identified, and the weight of the influence of these variables on the efficacy was evaluated.
Study: NCT05730192

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CADDIE
Description: A colonoscopy is an examination of the bowels using a colonoscope, or a thin, flexible tube with a light and camera. It can help identify issues like colorectal cancer, polyps, and ulcers.
Study: NCT04925466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP at pressure of 10 cmH2O
Description: Patients used CPAP with the pressure of 10 cmH2O during overnight polysomnography

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP at minimal effective pressure
Description: Patients with OSA will be treated with CPAP at minimal effective pressure derived from manual titration during sleep.
Study: NCT05730192

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CADDIE
Description: A colonoscopy is an examination of the bowels using a colonoscope, or a thin, flexible tube with a light and camera. It can help identify issues like colorectal cancer, polyps, and ulcers.
Study: NCT04915755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered.
Study: NCT05901688

Intervention type: OTHER
Intervention: Umbilical cord measurements & observations
Description: In the screening study of an unselected population at 20-22 weeks' and 35-37 weeks' gestation, women are offered an ultrasound scan as part of standard care and will be invited to take part in the study which will involve taking the following additional ultrasound measurements:~1. Umbilical cord coiling index (UCI)~2. Transverse diameter of umbilical cord (UC)~3. Transverse diameter of umbilical vein (UV) and artery (UA)~4. Umbilical vein (UV) Doppler flow characteristics~5. Presence of nuchal cord
Study: NCT04915755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered
Study: NCT05453929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium for deep NMB
Description: Deep neuromuscular blockade will be maintained using continuous infusion of rocuronium.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium for moderate NMB
Description: Moderate neuromuscular blockade will be maintained using continuous infusion of rocuronium.
Study: NCT04851041

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Potato
Description: Controlled human intervention trial to evaluate the impact of boiled potato intake as part of a healthy dietary patterns on cardiometabolic health

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pasta/rice
Description: Since potatoes, white rice and white pasta are all products with a high glycemic index and concomitant relatively steep glucose excursions after intake, this intervention group helps to compare the effect of potato vs another high glucemic index food.
Study: NCT05089682

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS Stimulation during sleep
Description: Open and closed-loop electrical modulation triggered and based on ongoing sleep staging by researcher as well as automated closed-loop algorithm for stimulation.
Study: NCT04657614

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neutral Alignment
Description: Alignment that is a neutral replicate of the participants prescribed prosthesis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anterior Alignment
Description: Alignment that is anterior displaced pylon.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Posterior Alignment
Description: Alignment that is posteriorly displaced pylon.
Study: NCT05568654

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Rapid Diagnostic Testing
Description: Eligible patients in hospitals randomized to this arm will undergo testing for viral pathogens (from November-April) and pneumococcal UAT testing. A CDSS-based alert will be generated in real time. If the patient is not being admitted to the intensive care unit, the form will append orders for viral pathogen and UAT testing.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Rapid Diagnostic Testing
Description: Eligible patients in hospitals randomized to this arm will undergo testing for viral pathogens (from November-April) and pneumococcal UAT testing. A CDSS-based alert will be generated in real time. If the patient is not being admitted to the intensive care unit, the form will append orders for viral pathogen and UAT testing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist-led de-escalation
Description: A CDSS algorithm will identify CAP patients who meet study criteria and have negative culture results for greater than 48 hours and generate a list for the antimicrobial stewardship pharmacist, who will be a member of the study team. The alerts will be audited by the pharmacist daily at a centralized location. The pharmacist will attempt to determine whether each patient is clinically stable. The validated measures of clinical stability in patients with CAP are a) resolved vital sign abnormalities (temperature, heart rate, oxygen saturation, blood pressure and respiratory rate) b) normal mental status and c) ability to eat. If the patient appears stable, the pharmacist will communicate their recommendations for de-escalation to the clinical providers via a phone call or page. The de-escalation recommendations made by the pharmacist will be based on a protocol developed by the research team.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist-led de-escalation
Description: A CDSS algorithm will identify CAP patients who meet study criteria and have negative culture results for greater than 48 hours and generate a list for the antimicrobial stewardship pharmacist, who will be a member of the study team. The alerts will be audited by the pharmacist daily at a centralized location. The pharmacist will attempt to determine whether each patient is clinically stable. The validated measures of clinical stability in patients with CAP are a) resolved vital sign abnormalities (temperature, heart rate, oxygen saturation, blood pressure and respiratory rate) b) normal mental status and c) ability to eat. If the patient appears stable, the pharmacist will communicate their recommendations for de-escalation to the clinical providers via a phone call or page. The de-escalation recommendations made by the pharmacist will be based on a protocol developed by the research team.
Study: NCT05434260

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgiphor Irrigation Solution
Description: use of Surgiphor wound irrigation solution during surgery

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sterile saline
Description: Use of sterile saline as a irrigation solution during surgery
Study: NCT04780763

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Milk product fermented by lactic bacteria or not fermented
Description: 2 bottles of 100g consumed daily during 28 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Milk product fermented by lactic bacteria or not fermented
Description: 2 bottles of 100g consumed daily during 28 days
Study: NCT05595889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: 250 mg/day p.o. QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Participants will receive irinotecan，100 mg/m2，Intravenous drip, day 1 and day 8 of every 3 weeks
Study: NCT06171776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RetroMTA
Description: calcium silicate lining material work as dentin substitute

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TheraCal
Description: calcium silicat material light cured

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fuji IX
Description: filling material bonded chemically to the tooth structure
Study: NCT05597592

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Feasability of a personalised physical rehabilitation program at home
Description: Monitoring of the realization of a personalised physical rehabilitation program at home by patients with neuromuscular and neurodegenrative disease
Study: NCT04543188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07284890
Description: PF-07284890 will be administered orally, daily for 21 consecutive days (21-day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07284890
Description: PF-07284890 will be administered orally, daily for 21 consecutive days (21-day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07284890
Description: PF-07284890 will be administered orally, daily for 21 consecutive days (21-day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07284890
Description: PF-07284890 will be administered orally, daily for 21 consecutive days (21-day cycle)
Study: NCT05157139

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Capsule
Description: Oral Capsule of vanillin \& wheat germ oil
Study: NCT04543188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07284890
Description: PF-07284890 will be administered orally, daily for 21 consecutive days (21-day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07284890
Description: PF-07284890 will be administered orally, daily for 21 consecutive days (21-day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07284890
Description: PF-07284890 will be administered orally, daily for 21 consecutive days (21-day cycle)
Study: NCT04964596

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: colonoscopy
Description: colonoscopy

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: FIT test
Description: faecal immunochemical test

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CT colonography
Description: noninvasive medical imaging technique that uses computed tomography to visualize the interior of the colon and rectum especially to screen for polyps or cancerous growths
Study: NCT06583785

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Black rice (Intervention)
Description: 210 g of cooked black rice

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Black rice (Intervention)
Description: 210 g of cooked black rice
Study: NCT04778189

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: while patients in group( NS ) will receive 500-mL normal saline IV in 5-10 minutes, after spinal anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: i.v dexmethasone
Description: patients in group( SD )will receive 8-mg dexamethasone IV in 500-mL normal saline after spinal anesthesia
Study: NCT06083376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal Stabilization Exercise
Description: Spinal stability exercises are commonly used isometric and isotonic exercises. A spinal stabilization exercise training program will be applied to the exercise group participants using the telerehabilitation method (simultaneous connection) 3 days a week for 8 weeks and a total of 24 sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical activity counseling
Description: Control group participants will first be given initial evaluations and verbal physical activity recommendations will be given. Patients will be contacted by phone at the 2nd, 4th and 6th weeks and reminded about the importance of physical activity.
Study: NCT06583785

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brown rice (Control)
Description: 210 g of cooked brown rice

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Brown rice (Control)
Description: 210 g of cooked brown rice
Study: NCT04543188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07284890
Description: PF-07284890 will be administered orally, daily for 21 consecutive days (21-day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07284890
Description: PF-07284890 will be administered orally, daily for 21 consecutive days (21-day cycle)
Study: NCT05534594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-PSMA-1007
Description: As explained under 'Arms'.
Study: NCT06583772

Intervention type: DIAGNOSTIC_TEST
Intervention: VR-based 9-hole peg test
Description: The volunteers will first undergo a physical 9-hole peg test. After the physical test is completed, the VR-based 9-hole peg test will be performed.
Study: NCT04723940

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bactrim
Description: Bactrim will be given for 6 weeks to treat joint infection
Study: NCT05094908

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arnica Tincture
Description: Arnika tincture is a topical plant-based preparation legally authorized in Colombia and in the countries of the European community, the product of this study is Arnika tinktur Gehrlicher (5249), manufactured by Gehrlicher Pharmazeutische Extrakte GmbH, Germany. According to the European Pharmacopoeia, the solution is a 70% hydroethanolic tincture prepared from the flowers of A. montana L, and composed at least 0.04% of sesquiterpene lactones. Arnica tincture will be applied topically by each participant on all lesions until day 30 or 45, depending on the regimen to be evaluated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arnica Tincture
Description: Arnika tincture is a topical plant-based preparation legally authorized in Colombia and in the countries of the European community, the product of this study is Arnika tinktur Gehrlicher (5249), manufactured by Gehrlicher Pharmazeutische Extrakte GmbH, Germany. According to the European Pharmacopoeia, the solution is a 70% hydroethanolic tincture prepared from the flowers of A. montana L, and composed at least 0.04% of sesquiterpene lactones. Arnica tincture will be applied topically by each participant on all lesions until day 30 or 45, depending on the regimen to be evaluated.
Study: NCT04723940

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bactrim
Description: Bactrim will be given for 6 weeks to treat joint infection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefadroxil
Description: Cefadroxil will be given for 6 weeks to treat joint infection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefadroxil
Description: Cefadroxil will be given for 6 weeks to treat joint infection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline Hcl
Description: Doxycycline HCl will given for 6 weeks to treat joint infection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline Hcl
Description: Doxycycline HCl will given for 6 weeks to treat joint infection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: Clindamycin will given for 6 weeks to treat joint infection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: Clindamycin will given for 6 weeks to treat joint infection
Study: NCT05567055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: Capmatinib is a medication for the treatment of metastatic non-small cell lung cancer tumors that have a mutation that leads to the exon 14 skipping of the MET gene, which codes for the membrane receptor HGFR
Study: NCT05543941

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XPERIENCE Advanced Surgical Irrigation
Description: The patient will undergo THA, TKA, or HR with irrigation of the deep wound prior to fascial closure consisting of XPERIENCE Advanced Surgical Irrigation (XP). XP solution will be applied prior to fascial closure and left to soak for up to 3 minutes. Remaining product will be suctioned away throughout the procedure. No rinsing should take place after irrigation and surgical site will be closed according to site standard operating procedures.
Study: NCT04543188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Binimetinib will be administered together with PF-07284890 orally, 45mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Binimetinib will be administered together with PF-07284890 orally, 45mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Binimetinib will be administered together with PF-07284890 orally, 45mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Binimetinib will be administered together with PF-07284890 orally, 45mg twice daily
Study: NCT04984629

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HYDRAFIL
Description: The HYDRAFIL System contains the following items: the Delivery System and the Pressure Gauge. The HYDRAFIL implant is contained within a pre-filled syringe that is inserted into the delivery system housing during the manufacturing process. The implant is heated within the delivery system prior to use to ensure a flowable implant that can be injected through a standard coaxial needle.
Study: NCT05905692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L Carnitine
Description: L carnitine will be given to group 1 (20 mg/kg/day) 3 times per week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: L Carnitine
Description: L carnitine will be given to group 1 (20 mg/kg/day) 3 times per week
Study: NCT06454227

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous washing
Description: subcutaneous washing with chlorhexidine gluconate prior to skin closure

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: no subcutaneous washing
Description: no washing
Study: NCT06205459

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: deep marginal acquisition using thermacut bur
Description: thermacut bur is a tool which doesn't contain any abrasives so it is much safer on the root surface of both prepared and adjacent teeth, and yields better treatment outcome in cases when exposing deep margins is needed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: deep marginal acquisition using thermacut bur
Description: thermacut bur is a tool which doesn't contain any abrasives so it is much safer on the root surface of both prepared and adjacent teeth, and yields better treatment outcome in cases when exposing deep margins is needed.
Study: NCT04920305

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phosphatidylserine
Description: subjects in the treatment group oral the PS (600mg/d, q.d.) for 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Bean powder
Description: Subjects in the control group were given a placebo, which was the same shape of bean powder(600mg/d, q.d.).